OrthoPediatrics Corp. Appoints Samuel D. Riccitelli to its Board of Directors

WARSAW, Ind., Dec. 15, 2017 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the appointment of Samuel D. Riccitelli to its Board of Directors as an independent member, effective immediately. The appointment of Mr. Riccitelli brings the Company’s Board to 11 members. Mr. Riccitelli will be a member of the Governance Committee of the Board.

Terry Schlotterback, Chairman of the OrthoPediatrics Board of Directors, said, “Sam brings a wealth of direct experience to the OrthoPediatrics Board that includes building medical technology companies that transitioned from private to public ownership. He also has a strong understanding of the process of novel technology development. I am excited to welcome Sam to the Board of Directors and look forward to leveraging his extensive background in the healthcare industry.”

Mr. Riccitelli, age 58,  has more than 30 years of experience in healthcare, including senior leadership positions at two publicly traded companies, and currently serves as Chairman of the Board of Directors of Precipio Diagnostics (NASDAQ:PRPO). From 2012 to 2017, he served as President and Chief Executive Officer, and as a Director, at Signal Genetics, Inc., a publicly traded molecular diagnostic company that was sold to miRagen Therapeutics. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc. (“Genoptix”), a publicly traded diagnostic company that was sold to Novartis in 2011. During his 10 year tenure at Genoptix, the company completed an initial public offering and grew sales to approximately $200 million in seven years.

From 1995 to 2001, Mr. Riccitelli served in a number of R&D and general management positions for Becton, Dickinson and Company, including as a Vice President and General Manager, and as a board member for BD Ventures, L.L.C., a venture capital fund of BDX. Mr. Riccitelli also served on the Board of Directors of Exagen Diagnostics, Inc., from 2011 to 2014. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas in Mechanical & Biomedical Engineering.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 23 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 35 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Primary Logo

 

© GlobeNewswire 2017

NuVasive Appoints Experienced Spine Executive Michael Piccirillo To Lead New Global Surgeon Education Platform

SAN DIEGODec. 14, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today the expansion of its renowned surgeon education program into a Clinical Professional Development (CPD) global platform for surgeons that integrates surgical training with professional development. This new initiative will be led by Michael Piccirillo, a recognized expert in designing and executing spine educational curriculums and surgeon communities in more than 80 countries across the world.

In 2003, NuVasive revolutionized spinal surgery by introducing an innovative lateral approach with its XLIF® technology. To better serve the spine surgeon community, NuVasive created and delivered a new standard in surgeon training. Through new product design, surgeon education and a leading sales team, XLIF is now the world’s leading procedure for the lateral approach. NuVasive is again taking the lead and evolving its education platform to better match the lifelong training needs and challenges facing today’s and tomorrow’s communities of spine surgeons.

The NuVasive CPD team will support the Company’s surgeon partners for the lifetime of their careers. The new training programs will facilitate the development of a diverse set of competencies that spine surgeons will need in the future and will deliver challenging programs that are surgeon-oriented, personalized and fit within a systematic pathway. Additionally, a core component of the expanded platform is peer-to-peer engagement to encourage collaboration of ideas and innovation among the surgeon participants and drive further engagement.

“As a leader in disruptive spine technologies, our commitment to surgeon training and education programs has been a key differentiator for NuVasive and has enabled us to introduce less invasive approaches to spine surgery, while also adapting to surgeon needs in the changing landscape of the industry,” said Gregory T. Lucier, chairman and chief executive officer of NuVasive. “The newly designed and expanded program is being rolled out globally to meet the needs of our surgeons and I’m excited to see the direction Michael is taking this critical and differentiating part of our business. Michael brings a wealth of knowledge and expertise in global educational strategy to NuVasive to make our CPD platform the most sought-after program available to surgeons around the world.”

Piccirillo joins NuVasive with more than 30 years of experience in developing strategy, building educational platforms and designing management solutions in the health care field. Piccirillo most recently served as managing partner at VALUGEN GmbH in Zurich. VALUGEN provides project-based services to help hospitals transform their spine centers into Centers of Excellence. While there, Piccirillo worked with a number of academic organizations to redesign their educational programs and created strategies for patient organizations. Before his time at VALUGEN, Piccirillo was the executive director at AOSpine and AOTrauma, the spine and trauma divisions of the AO Foundation, a Swiss-based non-profit organization which is partnered with and provides educational support for Synthes (DePuy Synthes). During his time at the AO Foundation, Piccirillo transformed both divisions into the largest communities of spine and trauma surgeons, respectively. Key to this success was the development of novel lifelong learning education and faculty programs, integrated research projects and the establishment of the World Forum and Global Spine Congress events. Piccirillo was also directly responsible for creating the AOSpine/AOTrauma competency curriculum, faculty development, and fellowships, as well as surgeon assessment programs.

“Tomorrow’s spine surgeon will be very different from yesterday’s and even today’s—not only will they need to be outstanding surgeons, but they will also need to be great managers and leaders. Education is critical in changing the behaviors, competencies and performance of tomorrow’s surgeon,” said Piccirillo. “I’m thrilled to join NuVasive with its documented history in creating a disruptive change to the traditional approaches to spine surgery and spine education. Our new education platform will continue this theme, and I’m particularly excited to implement a novel approach to facilitate a surgeon’s lifelong engagement with NuVasive.”

Picirillo graduated from London University with a degree in medical microbiology and supplemented his science training with specific professional courses as well as marketing and business administration courses to move into health care business management. He also received a diploma in marketing from the Chartered Institute of Marketing and a business administration degree from the University of Warwick.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

FDA Panel Gives Thumbs Down to Spine Device

By Joyce Frieden, News Editor, MedPage Today/December 13, 2017

GAITHERSBURG, Md. — An FDA advisory committee voted 5-8 Tuesday, with one abstention, against recommending approval of the Barricaid prosthesis for partial anulus replacement in patients with herniated discs.

“There was a high rate of breakage of the device, a high rate of migration, and [there was] the unknown nature of [some endplate] lesions,” said Eli Baron, MD, of the Cedars Sinai Spine Center in Los Angeles, a member of the FDA’s Orthopaedic and Rehabilitation Devices Panel. Many of the users of the device would be younger patients, “most in their 30s and 40s, and we don’t know what will happen down the line.” He voted that the risks of the Barricaid device, which is manufactured by Intrinsic Therapeutics, outweighed its benefits.

But committee member Ty Subhawong, MD, of the University of Miami, disagreed. “[The device is] reasonably safe, and I think the major concerns were centered around the endplate lesions and while there were some theoretical concerns about harbingers of device failure …. the number of lesions observed was sufficient to reassure me that there is nothing catastrophic about these devices,” said Subhawong, who voted in favor of recommending approval. He added, however, that a post-approval study would be a good idea.

The committee also voted 12-1 that the device was shown to be effective in the patients it was indicated for, but by a vote of 5-9, they did not agree that the device was shown to be safe.

The Barricaid implant is a polymeric mesh that sits in the posterior intervertebral disc space; it is connected to a metallic anchor that is attached to the vertebral body, the FDA explained in a briefing document issued prior to Tuesday’s meeting. The implant comes with a delivery tool and manual surgical instruments, which are used in a posterior/posterolateral approach.

The Barricaid Anular Closure Device is a permanent implant used after a limited lumbar discectomy performed for treatment of lumbar radiculopathy. The device is designed to mechanically block an opening in the anulus, thereby maintaining the relative position of nucleus within the disc space to prevent reherniation following limited discectomy in patients with large anular defects at an increased risk of reherniation.

 

READ THE REST HERE

AlloSource Announces Raime Leeby Muhle As Chief Financial Officer

Stimwave Appoints Industry Veteran Jim Surek as Chief Commercialization Officer and Adds Konstantin Slavin, M.D. to Medical Advisory Board

December 14, 2017

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced the appointment of Konstantin Slavin, M.D. to its medical board of advisors and the appointment of industry veteran Jim Surek to the position of chief commercialization officer. The expansion of the team is in direct response to an ever-increasing demand for its Freedom Spinal Cord Stimulation (SCS) System and StimQ Peripheral Nerve Stimulator (PNS) System for the treatment of chronic pain.

“Every day, increasing numbers of patients are seeking non-opioid solutions to managing chronic pain, and it is essential that we do everything we can to meet that demand and to serve those patients,” said Laura Tyler Perryman, co-founder and CEO of Stimwave. “The addition of Dr. Slavin and Jim Surek strengthens our executive management team to support our high growth and to meet these market needs.”

Dr. Slavin currently serves as professor of neurosurgery at the University of Illinois at Chicago and holds several leadership roles in professional societies, including serving as president of the American Society for Stereotactic and Functional Neurosurgery and as the director at large for the International Neuromodulation Society. He is a world-renowned expert in neuromodulation, most recently publishing his second edition of “Peripheral Nerve Stimulation” and “Neurostimulation: Principles and Practice.”

“This miniature, wireless stimulator minimizes the need for surgery in patients who are already suffering from pain, while allowing on-going care and full-body MRI scan capabilities providing a viable, non-opioid option for long-term pain management,” said Dr. Slavin. “I am pleased to join their prestigious board of experts in the field.”

A 25-year industry veteran, Jim Surek joins the Stimwave team as the company’s first chief commercialization officer. Surek received his Master’s in International Management from the Thunderbird School of Global Management. Beginning his career as a spinal implant sales representative at Medtronic in 1994, Surek rose through the ranks to vice president of sales and development before taking on the role of the first vice president of sales at Advanced Bionics in 2003, which ultimately sold to Boston Scientific. He went on to become the vice president of sales at Entellus Medical, Inc., which sold to Stryker earlier this month.

“I’m thrilled to return to the field of neuromodulation with Stimwave. It’s an exciting time to be a part of a great neuromodulation team and company setting the vision for the future for all pain patients across the country,” said Surek. “Stimwave’s technology brings the future forward through its miniaturization of the electronics and elimination of a bulky, potentially dangerous implantable battery. Now, physicians have a solution to treat a tremendously larger pain patient population, since more than 80 percent of patients either cannot receive treatment or refuse the surgery option to treat their pain.”

Stimwave’s devices use Wireless Pain Relief® technology and are 95 percent smaller than any other neuromodulation device on the market and can be anchored through an injectable method. The device delivers small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief. Stimwave launched its FDA-cleared devices for the relief of chronic back and leg pain to a limited number of patients throughout 2015. In March 2016, Stimwave was granted FDA 510(k) for the relief of peripheral nervous system (PNS) pain, becoming the only neuromodulation device manufacturer cleared by the FDA to help reduce chronic neuropathic pain at most locations throughout the body, from back and leg pain addressed by spinal cord stimulation to PNS treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.

About Stimwave

Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management. www.stimwave.com

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

Contacts

Glodow Nead Communications
Evan Nicholson, Rosemary O’Brien, Kati Stadum, and Sarah Rogers, 415-394-6500
StimwavePR@GlodowNead.com

Kuros Biosciences Announces Management Succession

Schlieren (Zurich), Switzerland, December 14, 2017

Kuros announced today the appointment of Michael Grau as Chief Financial Officer (CFO) effective February 1, 2018. Michael Grau succeeds Harry Welten, who will step down as CFO on February 1, 2018 to focus on his board roles and part-time CFO functions in privately held companies. Harry Welten will remain on the Board of Directors of Kuros.

Kuros’ Chief Executive Officer Dr. Joost de Bruijn commented: “I am delighted to welcome Michael Grau to the executive team. Michael has extensive experience in corporate finance and auditing in private and public companies. With his strong operational background, we believe Michael brings highly relevant experience and financial leadership to the Company that will help us as we capitalize on new opportunities to becoming a leading commercial-stage orthobiologics company.”

Joost de Bruijn continued: “I am sincerely grateful to Harry for leading the company through capital raises, restructurings, mergers and acquisitions in the past seven years. Harry’s continued involvement will ensure a smooth transition to Michael.”

Kuros’ Chairman Christian Itin said: “We are grateful for Harry’s valuable contributions and services to the Company. As CFO, Harry restructured CHF 70 million in private and public debt and raised more than CHF 80 million in equity, ensuring that the company has a solid capital base and structure for its next steps of growth and start of commercialization. We wish Harry all the best for his future endeavors.”

Christian Itin continued: “With Michael’s extensive experience as CFO of several small- and medium-sized companies, accounting and fundraising background, we have found a highly capable successor to Harry to help lead the company during its next growth stage. Michael has more than 15 years of experience in the medtech and pharma field and is therefore extremely well suited to take up this position.”

Biographical background on Michael Grau

Michael Grau has an impressive track record of 25 years` experience in corporate finance, controlling, accounting and general management in diverse industries and, since 2001, with a focus on medtech, biotech and pharma. He was responsible for multiple capital market transactions, financing rounds and several merger and acquisition agreements for public and private companies. Most recently, Mr. Grau served as CFO of Proteros Biostructures, a biotech company focusing on enabling lead discovery, Correvio, a Geneva-based hospital specialty pharma company, and Endosense, another Geneva-based private medtech company. He started his career working for KPMG Pat Marwick. Mr. Grau holds a BA in European Finance and Accounting from Bremen University, Germany, and Leeds University, U.K., and an executive MBA from Henley Business School at the University of Reading, U.K. Mr. Grau is citizen of Germany.

For further information, please contact:

Harry Welten, MBA

Chief Financial Officer

Phone +41 79 750 15 64

harry.welten@kurosbio.com

 

Joost de Bruijn

Chief Executive Officer

Phone +31 621 21 7603

joost.de.bruijn@kurosbio.com

About Kuros Biosciences AG

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

News release (pdf)
Kuros Biosciences Ltd, Wagistrasse 25, CH-8952 Schlieren

Willamette Surgery Center First in Oregon to Receive Advanced Certification for Total Hip and Total Knee Replacement

SALEM, Ore.Dec. 12, 2017 /PRNewswire/ — Willamette Surgery Center, in partnership with Hope Orthopedics of Oregon, is the first facility in Oregon to receive advanced certification for outpatient total hip and total knee replacement. Advanced Certification for Total Hip and Total Knee Replacement from The Joint Commission focuses on all aspects of outpatient hip and knee replacement, from pre-operative consultation to rehab and follow up visits. This achievement goes above and beyond the Joint Commission Accreditation, which Willamette Surgery Center has achieved and maintained since opening in 1999.

The surgeons of Hope Orthopedics have performed 375 joint replacements at Willamette Surgery Center since the start of the program in 2014.

When asked about the success of the partnership program of Willamette Surgery Center and Hope Orthopedics, Dr. John Coen, Hope Orthopedics surgeon and head of the outpatient total joint replacement program says, “It is great to see validation of something the surgeons at Hope Orthopedics already knew – Willamette Surgery Center does a fantastic job caring for our patients. It is a pleasure for Hope Orthopedics to bring outpatient joint replacement to the people of the Willamette Valley, and Willamette Surgery Center does it right.”

Willamette Surgery Center underwent a rigorous onsite review to qualify for advanced certification. Joint Commission experts evaluated compliance with advanced care standards and total hip and total knee replacement requirements, including orthopedic consultation, and pre-operative, intraoperative and post-surgical follow-up care.

Advanced Certification assures the public that standardized processes are in place to reduce the risk of error and improve the delivery of safe patient care.

About Willamette Surgery Center and Hope Orthopedics: Willamette Surgery Center and Hope Orthopedics are based in Salem, Oregon. Their partnership to bring outpatient total joint replacement to the area began in 2014. You can see more in this video about the outpatient joint replacement process at Hope Orthopedics and WSC.

Founded in 1951, The Joint Commission seeks to improve health care for the public by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. An independent, nonprofit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

 

SOURCE Willamette Surgery Center

Related Links

http://willamettesurgerycenter.com

Rep. Erik Paulsen Co-Sponsor of Bill to Suspend Collecting Medical Device Tax

– Some members of the House Ways and Means Committee, including Minnesota Republican Erik Paulsen, want to suspend collection of a medical device tax for five more years.

Paulsen and Republican colleague Jackie Walorski of Indiana on Tuesday introduced a bill to keep the tax from being collected through 2022. The proposal comes as time runs out on the current two-year moratorium that stopped device companies from having to pay a 2.3 percent sales tax on gross receipts in 2016 and 2017.

“Full repeal is my top priority,” Paulsen said.

But for now, he said, a five-year moratorium seemed like the best available vehicle to keep the tax from coming back Jan. 1. Paulsen believes his proposal can be attached to any of a number of year-end spending measures.

Going forward, Paulsen thinks he makes “a good selling argument” for permanent repeal based on the device companies’ willingness to expand operations by investing tax savings realized during the current moratorium.

The device tax was part of the Affordable Care Act. Collected from 2013 to 2015, it produced more than $5 billion in federal revenue. But it has long been targeted for repeal by the medical device industry, including hundreds of Minnesota medical technology businesses.

 

 

READ THE REST HERE

NuVasive To Acquire SafePassage

SAN DIEGODec. 12, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, and SafePassage™, a privately-held provider of intraoperative neurophysiological monitoring (IONM) services, announced today that they have entered into a definitive agreement under which NuVasive will acquire SafePassage. Terms of the deal were not disclosed.

With the addition of SafePassage, NuVasive Clinical Services™ (NCS) solidifies its leadership position as the largest provider of outsourced IONM services with more than 550 neurophysiologists and oversight physicians in the U.S., allowing for the delivery of services to over 1,000 customers and 3,000 surgeons. This joining of forces strengthens the Company’s intraoperative neuromonitoring business line, which was formed in July 2016 when the Company acquired Biotronic NeuroNetwork and combined its service offerings with that of the Company’s subsidiary, Impulse Monitoring, Inc. Since then, NCS has further scaled the business, achieving operational efficiencies and driving better clinical outcomes. Following the acquisition of SafePassage, NCS is expected to support greater than 100,000 IONM cases annually in the U.S.

SafePassage is also complementary to the current NCS geographical footprint with limited overlap between existing healthcare accounts. The acquisition helps further accelerate the services business growth and enables deeper reach in key strategic markets while adding significant new coverage, particularly in the densely populated New York region and along the East Coast where NuVasive has traditionally had a strong spine procedural-selling presence.

“The acquisition of SafePassage advances the NuVasive services strategy and expands our ability to transform how spine procedures are approached, measured and valued from a clinical and economic perspective,” said Skip Kiil, executive vice president, Global Commercial of NuVasive. “As the only spine company in the world with dedicated neuromonitoring services operating at this elevated scale, and now with increased case coverage, we are uniquely positioned to deliver greater value across our procedurally-integrated portfolio.

“Just as important, the highly trained and well-respected SafePassage leadership and clinicians have earned the industry reputation of being among the best in the business, and we’re excited to partner with them to provide consistent and quality care to hundreds of surgeons and thousands of patients each year,” continued Kiil.

“For more than a decade, the team at SafePassage has been dedicated to serving patients and surgeons with premium quality intraoperative neurophysiological monitoring services to improve patient outcomes and reduce economic risk for hospitals and surgeons,” said Dan Siegel, chief executive officer of SafePassage. “We are extremely passionate about our vision to eradicate preventable healthcare injury, the third leading cause of death in the United States, and I look forward to joining forces with NuVasive to further our mission worldwide.”

Financial
NuVasive expects the transaction to be accretive to the Company’s non-GAAP earnings per share (EPS) in 2018 and beyond. NuVasive also expects the transaction to support its longer-term targets for revenue growth and expansion of its non-GAAP operating and EBITDA margins. Additionally, the transaction is expected to meet the Company’s goals for return on invested capital for tuck-in acquisitions in three years, consistent with the Company’s previously stated acquisition criteria.

The transaction is expected to close in January 2018, subject to customary closing conditions.

About SafePassage
Founded in 2007 by surgeons, SafePassage’s 135 clinical specialists and support staff service approximately 12,600 cases annually. Privately held and based in New York City, SafePassage provides IONM and EEG services to surgeons and healthcare facilities across the eastern U.S. The Company is Joint Commission accredited since 2014, with recent renewal in 2017.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Forward-looking statements include, but are not limited to, statements about the timing of the anticipated acquisition, the potential benefits and synergies of the anticipated acquisition, including the expected impact on future financial and operating results, and post-acquisition plans and intentions. The forward-looking statements contained herein are based on the current expectations and assumptions of NuVasive and not on historical facts. The following important factors, among others, could cause actual results to differ materially from those set forth in the forward-looking statements: the satisfaction of conditions to closing the agreement, including the risk that any required conditions are not satisfied, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the acquisition; the loss of key employees; the risk that the businesses will not be integrated successfully; unexpected variations in market growth and demand for the combined company’s products and technologies; and the risk that benefits and synergies from the acquisition may not be fully realized or may take longer to realize than expected. Additional risks and uncertainties that may affect future results are described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Episurf Medical reaches milestone of 300 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of its 300th surgery with the Episealer® implant in the coming weeks.

“Strong clinical results, a growing user group among European surgeons, our 300th implant in production, a significant increase in the interest for the Episealer® technology within the orthopaedic industry, and most importantly, a continuous flow of successful patient outcomes. All of this sums it up, Episurf Medical is continuing to establish the Episealer® technology as a treatment alternative for early knee cartilage and bone damages“ says Pål Ryfors, CEO Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.30 CET on 12 December 2017.